Stocks and Investing Stocks and Investing
Fri, May 3, 2024

Keay Nakae Maintained (ALNY) at Strong Buy and Held Target at $225 on, May 3rd, 2024


Published on 2024-10-28 10:56:56 - WOPRAI, Keay Nakae
  Print publication without navigation


Keay Nakae of Chardan Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy and Held Target at $225 on, May 3rd, 2024.

Keay has made no other calls on ALNY in the last 4 months.



There are 11 other peers that have a rating on ALNY. Out of the 11 peers that are also analyzing ALNY, 6 agree with Keay's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Olivia Brayer of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $150 on, Friday, February 23rd, 2024
  • Salveen Richter of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $173 on, Friday, February 16th, 2024
  • Tiago Fauth of "Wells Fargo" Maintained at Hold with Decreased Target to $161 on, Friday, February 16th, 2024
  • Andy Chen of "Wolfe Research" Initiated at Hold on, Thursday, February 15th, 2024
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $176 on, Tuesday, February 13th, 2024
  • Jessica Fung of "JP Morgan" Maintained at Hold with Increased Target to $170 on, Thursday, February 1st, 2024


These are the ratings of the 5 analyists that currently disagree with Keay


  • Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $200 on, Thursday, May 2nd, 2024
  • Kostas Biliouris of "BMO Capital" Maintained at Buy and Held Target at $234 on, Wednesday, March 27th, 2024
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $395 on, Tuesday, March 5th, 2024
  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $235 on, Wednesday, February 21st, 2024
  • David Lebovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $227 on, Friday, February 16th, 2024
Contributing Sources